Vincerx Pharma, Inc. (NASDAQ:VINC – Get Free Report) was the target of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 433,200 shares, a decline of 29.3% from the May 31st total of 612,500 shares. Based on an average daily trading volume, of 717,900 shares, the short-interest ratio is currently 0.6 days.
Vincerx Pharma Stock Up 9.5 %
Vincerx Pharma stock opened at $0.81 on Monday. The company has a market capitalization of $23.92 million, a PE ratio of -0.45 and a beta of 1.41. Vincerx Pharma has a 12-month low of $0.57 and a 12-month high of $9.37. The firm’s fifty day moving average is $0.73 and its 200 day moving average is $2.06.
Vincerx Pharma (NASDAQ:VINC – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). Sell-side analysts expect that Vincerx Pharma will post -0.62 EPS for the current fiscal year.
Hedge Funds Weigh In On Vincerx Pharma
Analysts Set New Price Targets
Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Vincerx Pharma in a report on Tuesday, April 9th.
Get Our Latest Stock Report on VINC
Vincerx Pharma Company Profile
Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.
Read More
- Five stocks we like better than Vincerx Pharma
- Top Biotech Stocks: Exploring Innovation Opportunities
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Which Wall Street Analysts are the Most Accurate?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is the S&P 500 and How It is Distinct from Other Indexes
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Vincerx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.